Brief: Black Diamond Therapeutics Says Update On Phase 1 Dose Escalation Data In GBM Cohort Anticipated In Q4 2023
27/06/2023 13:10
June 27 (Reuters) - Black Diamond Therapeutics Inc
BDTX.O :
* BLACK DIAMOND THERAPEUTICS ANNOUNCES INITIAL DOSE
ESCALATION
DATA DEMONSTRATING ANTI-TUMOR ACTIVITY OF BDTX-1535 IN NON-SMALL
CELL LUNG CANCER PATIENTS ACROSS MULTIPLE EGFR MUTATION FAMILIES
* BLACK DIAMOND THERAPEUTICS- FAVORABLE TOLERABILITY PROFILE
OBSERVED WITH ONCE-DAILY THERAPEUTIC DOSES TO BE EXPLORED IN
NSCLC EXPANSION COHORTS
* BLACK DIAMOND THERAPEUTICS INC - UPDATE ON PHASE 1 DOSE
ESCALATION DATA IN GBM COHORT ANTICIPATED IN Q4 OF 2023
* BLACK DIAMOND THERAPEUTICS- MEETING WITH FDA IN Q4 OF 2023
TO
ALIGN ON DOSING STRATEGY TO ENABLE A POTENTIAL ACCELERATED
APPROVAL PATHWAY IN NSCLC
Source text for Eikon: ID:nGNX6vM2sK
Further company coverage: BDTX.O
((reuters.briefs@thomsonreuters.com;))